The blood thinner Pradaxa has generated about $1.48 billion in worldwide sales over a span of less than two years. According to a story in Bloomberg, that’s largely because manufacturer Boehringer Ingelheim has been marketing it as a more convenient alternative to an existing medication.
Unlike the blood thinner warfarin, which has been around since the 1950s, Pradaxa does not require frequent blood testing and dietary restrictions.
But plaintiffs in numerous ...
continue reading...